AICAR Research Overview (also known as AICA Ribonucleotide, Acadesine, 5-AICAR)
5-Aminoimidazole-4-carboxamide ribonucleotide — a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), the cellular energy sensor. AICAR is studied as an exercise mimetic that increases mitochondrial biogenesis, fatty acid oxidation, and endurance capacity without physical exertion. Research interest spans metabolic disease, obesity, and longevity.
What Is AICAR?
AICAR (5-aminoimidazole-4-carboxamide-1-β-ribofuranoside) is a synthetic analog of AMP that enters cells and is phosphorylated to ZMP — a compound that mimics the AMP/ATP ratio increase associated with energy depletion. This activates AMPK as if energy reserves were exhausted, triggering the same metabolic adaptations that exercise induces.
AMPK: The Exercise Signaling Hub
AMPK is the cell's master energy regulator. When activated — by exercise, caloric restriction, or AICAR — it simultaneously increases fatty acid oxidation, stimulates glucose uptake via GLUT4 translocation, inhibits energy-consuming anabolic processes, and promotes mitochondrial biogenesis via PGC-1α. These are collectively the metabolic adaptations associated with endurance training.
Exercise Mimicry Research
Landmark research demonstrated that AICAR administration in sedentary mice increased running endurance by 44% and upregulated a gene expression profile in skeletal muscle nearly identical to that of trained animals — without any exercise. This finding generated enormous research interest in AICAR as a tool for studying exercise biology and as a potential therapeutic for conditions where exercise is contraindicated.
Metabolic Disease Applications
AICAR has been studied extensively in models of type 2 diabetes, obesity, non-alcoholic fatty liver disease, and cardiac ischemia. It reliably improves insulin sensitivity, reduces hepatic fat accumulation, and protects cardiac tissue from ischemia-reperfusion injury in preclinical models.
Research Indications
AMPK Activation and Metabolic Reprogramming
AICAR's defining action is AMPK activation via ZMP accumulation. AMPK is the cell's master energy sensor — when activated, it switches metabolism from anabolic to catabolic mode: fatty acid oxidation increases, glucose uptake is enhanced, and protein/lipid synthesis is suppressed. AICAR is a primary research tool for probing exercise-induced metabolic pathways independent of mechanical stimulus.
Endurance Performance and Exercise Mimicry
Narkar et al. (2008) demonstrated that AICAR alone — without any training — increased running endurance of sedentary mice by 44% over 4 weeks via mitochondrial biogenesis and oxidative gene expression. This established AICAR as the prototypical exercise-mimetic research compound. WADA prohibited AICAR in 2011, acknowledging performance concerns before human data existed.
Insulin Resistance and Metabolic Syndrome
AICAR activates GLUT4 translocation to the cell surface in skeletal muscle via AMPK, independent of insulin signaling. This AMPK-driven glucose uptake pathway is intact even in insulin-resistant cells, making AICAR a tool for studying non-insulin-dependent glucose management in type 2 diabetes and metabolic syndrome models.
Cardioprotection / Ischemia-Reperfusion Injury
AICAR and its precursor acadesine have been investigated in cardiac surgery and ischemic heart disease models. AMPK activation provides myocardial protection during ischemic stress by shifting substrate use, reducing mitochondrial permeability transition, and attenuating cell death pathways. Phase II cardiac trials for acadesine showed mixed results in CABG patients.
Anti-Inflammatory and Immunomodulatory Research
AMPK activation by AICAR inhibits NF-κB and MAPK inflammatory signaling. Preclinical studies show reduced inflammatory cytokine production, attenuation of autoimmune disease severity in rodent models, and suppression of innate immune activation. These effects are secondary to the primary metabolic mechanism but have generated independent research interest.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Low / Entry | 5–10 mg | Daily or every other day | SubQ |
| Standard Research | 10–25 mg | Daily | SubQ |
| Maximum Explored | 25 mg | Daily | SubQ |
Note
WADA prohibits AICAR in competitive sport. Blood glucose monitoring is essential at all dose levels — AMPK activation drives cellular glucose uptake independent of insulin signaling.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
Both AICAR and metformin activate AMPK, but via different mechanisms (ZMP-mediated vs. mitochondrial complex I). Combined use creates additive AMPK activation with meaningfully elevated hypoglycemia risk. Use only with careful blood glucose monitoring and reduced doses of both.
Berberine activates AMPK (and other overlapping pathways with AICAR) via AMPK kinase-independent routes. The combination is largely redundant but not known to be synergistic. If combined, reduce doses of both — additive effects are possible.
Resveratrol activates SIRT1, which cross-activates AMPK through LKB1. The SIRT1-AMPK axis complements AICAR's direct AMPK activation, with the two agents acting at different points on the same metabolic sensor pathway. Animal co-administration studies show additive mitochondrial biogenesis effects.
GW501516 (a PPARδ agonist) was historically combined with AICAR in rodent performance studies. However, GW501516 was terminated in clinical development after demonstrating rapid cancer promotion across multiple tissue types in all animal species tested. The preclinical combination data does not justify its use; GW501516 is considered too hazardous for human research.
Reported Research Timeline
01Acute (hours after dose): ZMP accumulates intracellularly within hours of AICAR administration. AMPK activation triggers rapid GLUT4 translocation, increasing cellular glucose uptake within 30–90 minutes. Blood glucose may decrease measurably with active-dose protocols — monitor via glucometer before and 1–2 hours after each injection.
02Days 1–7 (metabolic switch initiation) (reported in cited studies): Continued AMPK activation begins shifting cellular metabolism toward fatty acid oxidation and away from glucose as primary fuel. PGC-1α expression increases, initiating mitochondrial biogenesis. In active rodent models, exercise-like gene expression patterns emerge within the first week.
03Weeks 2–4 (endurance and body composition effects in animal models) (reported in cited studies): The Narkar study's 44% endurance improvement emerged at 4 weeks of daily dosing. Lean mass preservation was observed alongside fat mass reduction. These outcomes are from sedentary mice — human translation is unestablished but is the basis for research interest.
04Post-cycle: AMPK-driven adaptations (mitochondrial density, GLUT4 expression, fat oxidation enzyme activity) may persist for 1–3 weeks after stopping AICAR. Blood glucose normalizes as ZMP clears within 24–48 hours of the last dose. Full 4–8 week off-cycle allows AMPK sensitivity to reset.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Cardiac / Cycle Length: Sustained AICAR use in rodent models was associated with cardiac hypertrophy (cardiomegaly). Maximum cycle length is 4 weeks; run in 4-week on / 4-week off blocks. Do not extend cycles or use continuously within a longer protocol, even if subjective effects are desirable.
Monitor blood glucose before each injection and 1–2 hours after. AICAR activates GLUT4 translocation via AMPK, driving glucose into cells independent of insulin — measurable blood glucose drops have been documented in active-dose protocols.
WADA prohibits AICAR in competitive sport. Athletes in tested sports must avoid entirely.
Short cycles only — 4 weeks is the maximum documented in the RUO community. Longer cycles have no safety data and increasing metabolic disruption risk.
No established human safety profile. All safety information is extrapolated from animal studies and a small number of academic metabolic trials. Long-term toxicity, reproductive effects, and drug interaction profiles are unknown.
Use standard aseptic subcutaneous injection technique. Rotate sites (abdomen and thigh most common). Localized irritation is possible.
Seek Medical Attention If:
Symptoms of hypoglycemia: dizziness, shakiness, sweating, confusion, rapid heart rate, weakness, or loss of consciousness. Consume fast-acting carbohydrates (glucose tablets, juice) immediately and seek emergency care if symptoms are severe.
Any severe or unusual adverse effect not otherwise explained — including cardiovascular symptoms or neurological changes.
Lactic acid can be elevated by AICAR through AMPK-mediated metabolic effects. Individuals with mitochondrial disorders or conditions predisposing to lactic acidosis should not use AICAR.
Metformin interaction — both AICAR and Metformin inhibit mitochondrial complex I. Combining them can compound lactic acidosis risk. If on Metformin, do not add AICAR without physician supervision and monitoring.
Quality Indicators
Verified Marker
HPLC Purity ≥98% with CoA
AICAR (MW 338.2 Da, also known as acadesine or AICA ribonucleoside) is a well-characterized nucleoside analog. Purity certificates should specify AICAR (acadesine), not the deaminated analog AICA or the free base AICA without the ribose moiety. Reputable suppliers provide HPLC chromatograms.
Verified Marker
Lyophilized Powder with Cold-Chain Shipping
AICAR is a nucleoside analog and is degraded by heat and moisture over time. Products that arrive at room temperature in powder form without cold-chain packaging (or explicit evidence of stability at room temp) carry a real degradation risk. Reconstituted solutions should be used promptly or stored at 2–8°C.
Quality Concern
Confusion with AICA vs AICAR
AICA (5-aminoimidazole-4-carboxamide) is the free base without the ribose group. It does NOT activate AMPK — that requires the riboside (AICAR). Suppliers mislabeling or confusing the two compounds represent a quality and safety issue. Confirm the product is 'acadesine' or 'AICA ribonucleoside' explicitly.
Quality Concern
No Independent Third-Party Testing
Given hypoglycemia risk and the absence of human safety data, sourcing AICAR without independent third-party verification is an elevated risk compared to other research compounds. Identity and purity verification via independent lab is essential.
Research Citations
Research Focus
AMPK activation, Mitochondrial biogenesis, Fat oxidation, Endurance, Metabolic health, Longevity
Verified Vendors Carrying AICAR
Frequently Asked Questions
What should researchers watch for with AICAR?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with AICAR?
Acute (hours after dose): ZMP accumulates intracellularly within hours of AICAR administration. AMPK activation triggers rapid GLUT4 translocation, increasing cellular glucose uptake within 30–90 minutes. Blood glucose may decrease measurably with active-dose protocols — monitor via glucometer before and 1–2 hours after each injection.
How is AICAR typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →